Angiotensin AT2 Receptor is Anti-inflammatory and Reno-Protective in Lipopolysaccharide Mice Model: Role of IL-10.

Lipopolysaccharide angiotensin II type 2 receptor interleukin-10 kidney injury neutralizing IL-10 antibody pro-inflammatory cytokines

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 28 08 2020
accepted: 16 03 2021
entrez: 3 5 2021
pubmed: 4 5 2021
medline: 4 5 2021
Statut: epublish

Résumé

Acute kidney injury (AKI) due to endotoxemic insult is predicted by the infiltration of neutrophils, monocytes and macrophages, and the release of pro-and anti-inflammatory cytokines to the site of injury. Earlier, we have demonstrated the role of angiotensin-II type 2 receptor (AT2R) stimulation in reno-protection in lipopolysaccharide (LPS)-induced inflammation and AKI in C57BL6/NHsd mice. Moreover, AT2R activation has been shown to increase the anti-inflammatory cytokine interleukin-10 (IL-10), its role in AT2R-mediated anti-inflammation and reno-protection is unknown. To address this question, in the present study mice were treated with the AT2R agonist C21 (0.3 mg/kg, intraperitoneally), LPS (5 mg/kg, intraperitoneally), or LPS with C21 pre-treatment with or without neutralizing IL-10 antibody. Treatment with C21 alone caused an increase in the plasma and kidney IL-10 levels, which peaks at 2-h, and returned to baseline at 6-h. The C21-induced IL-10 increase was blocked by the AT2R antagonist PD123319 suggesting AT2R's involvement. LPS treatment caused a profound increase in tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and the LPS-induced increase in these cytokines was attenuated by the C21 pre-treatment (1-h prior LPS) both in the plasma and kidney. Neutralizing IL-10 antibody treatment abrogated the C21-lowering of TNF-α and IL-6 in the kidney but not in the plasma. Similar results as related to the cytokines profiles in all the groups were also observed in the heart and spleen. The alteration in early cytokine profile prompted us to measure the markers of renal function (blood urea nitogen and urinary creatinine) in order to analyze the effect of IL-10 neutralization. However, it was too early to observe changes in renal function. Therefore, the renal function and injury markers were again measured at 24 h. Treatment with neutralizing IL-10 antibody attenuated the C21-mediated improvement in indices of the kidney function, but not the biomarkers of renal injury (kidney injury molecule-1 and neutrophil-gelatinase associated lipocalin). Collectively, our data suggest that the involvement of IL-10 in AT2R-mediated anti-inflammation and reno-protection against LPS is complex, mediating the renal cytokine profile and kidney filtration function, but not the plasma cytokine profile and renal injury markers.

Identifiants

pubmed: 33935698
doi: 10.3389/fphar.2021.600163
pii: 600163
pmc: PMC8082177
doi:

Types de publication

Journal Article

Langues

eng

Pagination

600163

Informations de copyright

Copyright © 2021 Fatima, Patel and Hussain.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Hypertension. 2013 Jun;61(6):1218-26
pubmed: 23547236
PLoS One. 2013 Dec 23;8(12):e84479
pubmed: 24376813
ISRN Nephrol. 2012 Nov 01;2013:394582
pubmed: 24967225
Circ Shock. 1992 Oct;38(2):145-52
pubmed: 1423923
Sci Rep. 2015 Jul 07;5:11822
pubmed: 26149595
Mol Immunol. 2006 Apr;43(10):1557-64
pubmed: 16263172
Annu Rev Pharmacol Toxicol. 2008;48:463-93
pubmed: 17937594
Hypertension. 2011 Feb;57(2):308-13
pubmed: 21189405
J Exp Med. 1993 Feb 1;177(2):547-50
pubmed: 8426124
J Clin Invest. 1999 Dec;104(12):1693-701
pubmed: 10606623
Biomed Pharmacother. 2019 Jun;114:108660
pubmed: 30974387
Nephron. 2018;140(2):140-143
pubmed: 29852498
BMC Nephrol. 2018 Feb 5;19(1):29
pubmed: 29402223
Am J Physiol Renal Physiol. 2011 Mar;300(3):F700-6
pubmed: 21209001
J Immunol. 1987 May 15;138(10):3475-80
pubmed: 3553327
Front Physiol. 2017 Oct 25;8:837
pubmed: 29118719
Biosci Rep. 2019 May 23;39(5):
pubmed: 31072913
Biomed Pharmacother. 2018 Apr;100:304-315
pubmed: 29448207
J Hypertens. 1999 Apr;17(4):537-45
pubmed: 10404956
Hypertens Res. 2015 Jan;38(1):21-9
pubmed: 25209104
J Am Soc Nephrol. 2016 Feb;27(2):371-9
pubmed: 26561643
Am J Physiol Renal Physiol. 2021 May 1;320(5):F814-F825
pubmed: 33719572
PLoS One. 2015 Jun 18;10(6):e0129260
pubmed: 26086868
Biology (Basel). 2020 Jul 06;9(7):
pubmed: 32640615
J Cell Mol Med. 2015 Aug;19(8):1975-85
pubmed: 25991381
J Cardiovasc Pharmacol. 2015 Apr;65(4):371-6
pubmed: 25590749
Kidney Int. 2020 May;97(5):904-912
pubmed: 32107020
Kidney Int Suppl. 2003 May;(84):S69-71
pubmed: 12694313
Compr Physiol. 2012 Apr;2(2):1303-53
pubmed: 23798302
Kidney Blood Press Res. 2016;41(6):911-918
pubmed: 27889773
J Neuroinflammation. 2016 Nov 24;13(1):297
pubmed: 27881137
Hypertension. 2016 May;67(5):906-15
pubmed: 27021008
J Immunol. 2010 Dec 1;185(11):6599-607
pubmed: 21041726
J Immunol. 2010 Nov 15;185(10):6286-93
pubmed: 20935205
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Nat Clin Pract Nephrol. 2009 Feb;5(2):89-100
pubmed: 19065132
J Am Soc Nephrol. 2015 Dec;26(12):3123-32
pubmed: 25855775
Hypertension. 2018 Sep;72(3):e20-e29
pubmed: 29987108
J Clin Invest. 2009 Oct;119(10):2868-78
pubmed: 19805915
J Immunol. 2005 Jun 1;174(11):7368-75
pubmed: 15905584
J Trauma Acute Care Surg. 2013 Apr;74(4):1005-13
pubmed: 23511138
J Am Soc Nephrol. 2007 Apr;18(4):1093-102
pubmed: 17329576

Auteurs

Naureen Fatima (N)

Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.

Sanket Patel (S)

Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.

Tahir Hussain (T)

Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.

Classifications MeSH